Heroes

The energy company didn't handle 21st-century solar power well, so she paid $400 electric bills.

Her neighbors are paying $18 a month. Joyce Villegas has been paying almost $400 a month for over three years because of delays from Hawaiian Electric, the state's utility company.

The energy company didn't handle 21st-century solar power well, so she paid $400 electric bills.

Solar energy is finally becoming affordable. People love it. Especially in Hawaii.

In fact, The New York Times decided to do a whole story about what's going on in Hawaii.

But some people in Hawaii haven't been able to enjoy the benefits of solar power until recently.

This is Joyce Villegas, a resident of Hawaii who requested solar panels from Hawaiian Electric, the state's energy company, over three years ago.


All her neighbors, who get their electricity from solar power, pay much less per month than she does.

This might seem like the classic story of a big mean energy company screwing over a little old lady.

But in this case, Hawaiian Electric isn't a villain as much as it is a company afraid of change.

When Hawaiian Electric realized how many people were opting for solar, they realized two things:

  1. Their infrastructure and grid might not be able to handle the changes.
  2. And, more importantly, they were afraid that they'd stop making money altogether.

Hawaiian Electric put a stop to new solar installations until they could figure out a way to handle the energy traffic on the grid and a way to make a profit. That's fair, right? Any company needs to be able to profit to survive.

But ... they continued collecting nearly $400 per month in electric bills from people like Joyce to make up for the fact that solar-powered customers were paying so much less.

You see, Hawaii has the highest energy costs in the entire United States.

They also have the most sun. So they're at the forefront of solar technology.

Not only is solar energy more affordable, but some of the time, the people whose homes run on the solar grid are actually producing more energy than they use, which the utility company compensates them for.

Hawaii is paradise, especially if you have solar panels and your energy company pays you.

Electric utility grids were originally designed to send power one direction — from the power plant into homes and buildings.

But solar power on the grid moves both ways.

When you don't use your solar energy, you send it back to the grid. The utility company's job includes maintaining that energy grid.

Upgrading the grid to handle solar energy being sent back to the utility is expensive. If you don't upgrade it, it can degrade your infrastructure, causing brownouts, blackouts, and other problems.

And this is a legitimate reason for Hawaiian Electric to be concerned about the increasing popularity of solar panels.

But that's not exactly what had them stalling on Joyce's solar panel installations...

As more people rely on solar energy, the energy companies make less money.

Hypothetically, say everyone switches to solar. If no one is paying the utility company, if they aren't needed to produce electricity but just to maintain the grid, they go bankrupt. If they go bankrupt, no one manages and sustains the grid.

Hawaiian Electric took too much time to adapt and a court ruled that they had to start allowing solar installations again.

They've promised to get 90% of the backlog out immediately.

Joyce Villegas finally got her solar panels approved. They're installing them soon.

The future is now. And utility companies will have to adapt to a new business model.

We are moving to a future where utility companies become storage centers, taking the extra solar power we don't use and redistributing it at night. Energy companies won't be generators as much as distributors, and that will take some getting used to as we become our own generators of clean energy.

Read more in The New York Times story.

via Ministry of Lands and Natural Resources-Ghana

Ghana kicked off an ambitious new program on Friday that its leaders hope will reverse over a century of significant deforestation and climate change. On June 11, the country celebrated its first Green Ghana Day by planting somewhere near five million trees.

"The exploitation of forest resources for national development has not been sustainable over the years," President Akufo-Addo said in a speech marking the country's inaugural Green Ghana Day.

"We don't have tomorrow or the day after tomorrow to do this. We have to act now," he added.

Ghana's current forest cover stands at 1.6 million hectares, down from 8.2 million in 1900, according to statistics from the Ministry of Lands and Natural Resources. Much of the West African country's forests have been degraded by small-scale illegal gold miners and the indiscriminate chopping of trees without reforestation.

Keep Reading Show less
via Ministry of Lands and Natural Resources-Ghana

Ghana kicked off an ambitious new program on Friday that its leaders hope will reverse over a century of significant deforestation and climate change. On June 11, the country celebrated its first Green Ghana Day by planting somewhere near five million trees.

"The exploitation of forest resources for national development has not been sustainable over the years," President Akufo-Addo said in a speech marking the country's inaugural Green Ghana Day.

"We don't have tomorrow or the day after tomorrow to do this. We have to act now," he added.

Ghana's current forest cover stands at 1.6 million hectares, down from 8.2 million in 1900, according to statistics from the Ministry of Lands and Natural Resources. Much of the West African country's forests have been degraded by small-scale illegal gold miners and the indiscriminate chopping of trees without reforestation.

Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer — most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving — and for longer — than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval — an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases — something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."